Independent · Educational · Not medical advice
Navigate peptide therapy without the chaos.
Plain-English guides, provider comparisons, and tracking tools for people considering GLP-1 and peptide-based treatments. We don't sell, prescribe, or endorse — we help you ask better questions.
Latest
Freshest articles
The most recent updates from our editorial team.
- Retatrutide's two-year trial data: what we learned at…Medications · 8 min
- FDA's compounded GLP-1 enforcement in 2026: what 55+…Industry & Regulation · 5 min
- ACHIEVE-3: the first head-to-head oral GLP-1 trial —…Medications · 4 min
- Beyond weight loss: what a Lancet review says about GLP-1 medicationsFoundations · 6 min
- Who stops a GLP-1 — and who comes back: what a 60,000-patient study foundMaintenance · 6 min
Peptide therapy is going mainstream. The consumer experience hasn't caught up.
Unclear legality
Branded, compounded, and 'research' products are sold side by side with very different legal footing.
Inconsistent provider quality
From async forms to board-certified follow-up — same category, very different oversight.
Bad education
Marketing copy answers most of what people read, and almost none of what they actually need to know.
Doctor-discussion checklist
“Am I ready for a GLP-1 conversation?”
Six questions. Tailored questions to bring to your clinician, a list of red flags to avoid online, and a starter tracking template. No diagnosis, no recommendation.
Take the 2-minute quiz- Questions to ask your clinician
- What to prepare before your appointment
- What not to buy online
- Starter tracking template
Provider transparency
Provider comparison, side by side
Independently researched. Pricing, oversight, and any public FDA or litigation history — surfaced before you sign up.
| Provider | Type | Monthly |
|---|---|---|
| 9amHealth | Branded | $149/mo |
| Amazon One Medical | Branded | $9/mo |
| Calibrate | Branded | $199/mo |
| CVS MinuteClinic Weight Loss | Branded | — |
| Eden | Both | $129/mo |
Last verified by our editorial team. Always confirm details with the provider before deciding.
Cornerstone guides
Start here
Medications
Retatrutide's two-year trial data: what we learned at…
Up to 30.3% average weight loss at two years in TRIUMPH-1. Here's what the Phase 3 data showed at ADA 2026 — and why retatrutide still isn't available by…
8 min read
Industry & Regulation
FDA's compounded GLP-1 enforcement in 2026: what 55+…
FDA issued more than 55 warning letters to telehealth companies in 2025-2026 for false and misleading claims about compounded GLP-1 products, and logged…
5 min read
Medications
ACHIEVE-3: the first head-to-head oral GLP-1 trial —…
ACHIEVE-3 is the first Phase 3 randomized trial to compare two oral GLP-1s. Foundayo (orforglipron) reduced A1C more than oral semaglutide in type 2…
4 min read
Foundations
Beyond weight loss: what a Lancet review says about GLP-1 medications
A 2026 Lancet Diabetes & Endocrinology review examined GLP-1 benefits across heart disease, kidneys, sleep apnea, and more. Here's what the evidence supports, where it's still preliminary, and what 'disease-modifying' actually means in this context.
6 min read
Maintenance
Who stops a GLP-1 — and who comes back: what a 60,000-patient study found
A 60,000-patient ENDO 2026 study found 4 in 10 people stop a GLP-1 within a year — and more than half eventually restart. Here's what the data shows.
6 min read
The weekly brief
A plain-English brief on GLP-1s, peptides, and the business behind them.
FDA updates, new studies translated, provider and pricing shifts, and one practical tracking tip — in your inbox once a week.